Sutimlimab in cold agglutinin disease
Study (n=24) found selective upstream inhibition of activity in the classic complement pathway rapidly halted haemolysis, increased Hb levels and reduced fatigue in patients receiving sutimlimab. At least 1 adverse event occurred during the treatment period in 22 patients (92%).
Source:
New England Journal of Medicine
SPS commentary:
Sutimilimab is a humanised monoclonal antibody that selectively inhibits an upstream serine protease within the C1-complex in the complement pathway, so preventing downstream signalling cascades, which results in phagocytosis, inflammation and cell lysis.
In May 2020 the FDA granted sutimilimub priority review of Biologics License Application (BLA) for sutimlimab for treatment of hemolysis in adult patients with cold agglutinin disease.